Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
IntroductionNon-small cell lung cancer (NSCLC) is the leading cause of cancer incidence and mortality worldwide. Neoadjuvant chemo-immunotherapy has led to clinical benefits in resectable NSCLC in comparison to chemo-therapy alone. Major pathological response (MPR) and pathological complete response...
Main Authors: | Greta Alì, Anello Marcello Poma, Iosè Di Stefano, Carmelina Cristina Zirafa, Alessandra Lenzini, Giulia Martinelli, Gaetano Romano, Antonio Chella, Editta Baldini, Franca Melfi, Gabriella Fontanini |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1115156/full |
Similar Items
-
Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023-04-01) -
Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer
by: Nicola Simoni, et al.
Published: (2020-12-01) -
Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery
by: Valerio Nardone, et al.
Published: (2022-06-01) -
Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
by: Sara Franzi, et al.
Published: (2022-05-01) -
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort
by: Rossella Bruno, et al.
Published: (2024-04-01)